Status:
UNKNOWN
Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Patients Hospitalized in the Hospices Civils of Lyon
COVID-19 Disease
Eligibility:
All Genders
18+ years
Brief Summary
Morphine is used in the treatment of dyspnea and polypnea with a proven benefit on the improvement of these symptoms, both etiologically and symptomatically. This medication is used in particular in p...
Eligibility Criteria
Inclusion
- Age over 18 years.
- Having had a Covid-19 respiratory disease confirmed by PCR or TDM or anamnestic criterion for patients living in communities for the elderly (respiratory symptomatology suggestive and at least 3 cases confirmed in the living environment).
- Having had respiratory severity criteria: respiratory distress syndrome including FR\> 25 / min and oxygen-demand\> 4 L / min to maintain a SpO2\> 90% at inclusion.
- Having had a defined level of care after collegial discussion notified in the file rejecting the external cardiac massage and admission to the intensive care unit (Level 3 and 4 on the protocols of the Hospices Civils de Lyon).
- Collection of non-opposition
Exclusion
- \-
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04522037
Start Date
June 1 2020
End Date
February 1 2021
Last Update
August 21 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital de la Croix Rousse / GHN
Lyon, France, 69004
2
Hôpital Edouard Herriot
Lyon, France, 69008
3
Hôpital Lyon Sud
Pierre-Bénite, France, 69445